These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11717593)

  • 1. Between Scylla and Charybdis: The choice of inotropic agent for decompensated heart failure.
    Felker GM; O'connor CM
    Am Heart J; 2001 Dec; 142(6):932-3. PubMed ID: 11717593
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical experience of a new inotropic agent--Prenalterol--in hypotension and heart failure.
    Reiz S; Waagstein F; Hjalmarson A
    Clin Cardiol; 1980 Apr; 3(2):96-105. PubMed ID: 6104553
    [No Abstract]   [Full Text] [Related]  

  • 3. Heart failure management: 25 years of progress.
    Sharpe N
    N Z Med J; 2001 Feb; 114(1125):23-4. PubMed ID: 11277469
    [No Abstract]   [Full Text] [Related]  

  • 4. Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of beta-blocker therapy in patients with heart failure: a proposal for a trial.
    Zampino M; O'Connor CM; Gattis WA; Adams KF; Gheorghiade M
    Am Heart J; 2003 Feb; 145(2 Suppl):S62-6. PubMed ID: 12594456
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial.
    Aranda JM; Schofield RS; Pauly DF; Cleeton TS; Walker TC; Monroe VS; Leach D; Lopez LM; Hill JA
    Am Heart J; 2003 Feb; 145(2):324-9. PubMed ID: 12595851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Usefulness of OPC-8212, an inotropic agent, in patients with chronic congestive heart failure--a multiple dose evaluation on its effect and arrhythmogenesis].
    Fukuda K; Handa S; Ogawa S; Nakamura Y; Kawamura Y
    Kokyu To Junkan; 1988 Oct; 36(10):1125-31. PubMed ID: 3247528
    [No Abstract]   [Full Text] [Related]  

  • 7. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.
    Perrone SV; Kaplinsky EJ
    Int J Cardiol; 2005 Sep; 103(3):248-55. PubMed ID: 16098385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of beta-blocker treatment in heart failure.
    Gilbert EM
    Rev Cardiovasc Med; 2002; 3 Suppl 3():S42-7. PubMed ID: 12447161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy.
    Stevenson LW
    Circulation; 2003 Jul; 108(4):492-7. PubMed ID: 12885733
    [No Abstract]   [Full Text] [Related]  

  • 11. Rationale and design of the enoximone clinical trials program.
    Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic cardiovascular support.
    Zaloga GP; Prielipp RC; Butterworth JF; Royster RL
    Crit Care Clin; 1993 Apr; 9(2):335-62. PubMed ID: 8490766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use of beta-blocker therapy in patients with heart failure: a practical guide.
    Doughty RN; Richards AM
    N Z Med J; 2001 Feb; 114(1125):36-8. PubMed ID: 11277474
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of chronic heart failure with beta-adrenoceptor antagonists. Guideline-based optimization with ERICA, a quality register].
    Antoni DH; Beuckelmann D; Hambrecht R; Nowak F; Schuchert D; Schwinger RH
    Dtsch Med Wochenschr; 2002 Nov; 127(46):2459-63. PubMed ID: 12432488
    [No Abstract]   [Full Text] [Related]  

  • 15. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.
    Triposkiadis F; Karayannis G; Giamouzis G; Skoularigis J; Louridas G; Butler J
    J Am Coll Cardiol; 2009 Nov; 54(19):1747-62. PubMed ID: 19874988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure.
    Kota B; Prasad AS; Economides C; Singh BN
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):269-78. PubMed ID: 19087950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Protocol-guide in clinical experimentation on inotropic drugs].
    Campolo L; Padrini R; Razzolini R; Klugmann S; Chioin R
    G Ital Cardiol; 1985 Jul; 15(7):695-9. PubMed ID: 4076703
    [No Abstract]   [Full Text] [Related]  

  • 19. [Beta receptor blockers: renaissance in therapy of heart failure].
    Klein W
    Wien Klin Wochenschr; 1997 Apr; 109(7):219-21. PubMed ID: 9206900
    [No Abstract]   [Full Text] [Related]  

  • 20. Inotropic drugs and neurohormonal antagonists in the treatment of HF in the elderly.
    O'Connor CM; Arumugham P
    Clin Geriatr Med; 2007 Feb; 23(1):141-53. PubMed ID: 17126759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.